Last reviewed · How we verify
SHR4640 dose1 plus Febuxostat dose1 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
SHR4640 dose1 plus Febuxostat dose1 (SHR4640 dose1 plus Febuxostat dose1) — Jiangsu HengRui Medicine Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SHR4640 dose1 plus Febuxostat dose1 TARGET | SHR4640 dose1 plus Febuxostat dose1 | Jiangsu HengRui Medicine Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SHR4640 dose1 plus Febuxostat dose1 CI watch — RSS
- SHR4640 dose1 plus Febuxostat dose1 CI watch — Atom
- SHR4640 dose1 plus Febuxostat dose1 CI watch — JSON
- SHR4640 dose1 plus Febuxostat dose1 alone — RSS
Cite this brief
Drug Landscape (2026). SHR4640 dose1 plus Febuxostat dose1 — Competitive Intelligence Brief. https://druglandscape.com/ci/shr4640-dose1-plus-febuxostat-dose1. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab